NEW YORK, NY / ACCESSWIRE / June 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

FibroGen, Inc. (NASDAQ:FGEN)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16552&wire=1
Lead Plaintiff Deadline: June 11, 2021
Class Period: October 18, 2017 - April 6, 2021

Allegations against FGEN include that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

ChemoCentryx, Inc. (NASDAQ:CCXI)

If you suffered a loss, contact us at:http://www.wongesq.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16552&wire=1
Lead Plaintiff Deadline: July 6, 2021
Class Period: November 26, 2019 - May 3, 2021

Allegations against CCXI include that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

PureCycle Technologies, Inc. (NASDAQ:PCT)